Boeing secures $883 million Army contract for cargo support services
On Friday, Lucid (NASDAQ:LCID) Capital Markets initiated coverage on Cybin Inc. (NYSE: CYBN), currently trading at $8.82 with a market cap of $185.54 million, with a Buy rating, setting a 12-month price target of $106 per share. The decision is based on Cybin’s innovative approach to developing alternative formulations and derivatives of psychedelic drugs. InvestingPro data shows the stock has gained nearly 11% in the past week.
The analyst highlighted the 75-year history of psychedelic drugs being researched for treating mental illnesses. According to the National Institutes of Health, 23% of U.S. adults suffer from mental health conditions, including depression, which underscores the potential impact of Cybin’s developments. InvestingPro analysis indicates the company maintains a strong balance sheet with more cash than debt, though it’s currently burning through cash reserves.
Cybin is noted for its creation of novel intellectual property (IP) by altering formulations and developing deuterated analogues of psychedelics. This strategy addresses the pharmaceutical industry’s general neglect of psychedelic drugs due to a lack of patent protection.
The company boasts the largest IP portfolio in its field, with 90 granted patents and over 230 applications pending. This extensive portfolio is a key factor in Lucid Capital Markets’ positive outlook on Cybin’s stock.
Cybin’s focus on addressing mental health challenges with innovative solutions positions it as a significant player in the pharmaceutical industry, according to Lucid Capital Markets.
In other recent news, Cybin Inc. has been granted a U.S. patent for its CYB004 program, aimed at treating generalized anxiety disorder, which is expected to extend exclusivity until 2040. The company is also advancing its CYB003 program, receiving a U.S. patent for this treatment targeting Major Depressive Disorder, with exclusivity projected until 2041. Cybin’s CYB003 has shown promising results in Phase 2 trials, leading to its current Phase 3 evaluation under the PARADIGM program. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to CYB003, potentially expediting its review process. Additionally, Cybin has partnered with Thermo Fisher Scientific (NYSE:TMO) to support the Phase 3 clinical supply and potential future manufacturing of CYB003. The company is conducting a Phase 2 study for CYB004, with completion expected around mid-2025. Cybin’s CEO has expressed support for the FDA’s focus on psychedelic drugs as innovative treatments for mental health conditions. The company continues to expand its clinical trial partnerships, aiming to revolutionize mental healthcare with its investigational compounds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.